Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis

References

• LozanoRNaghaviMForemanKGlobal and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201230898592095212810.1016/S0140-6736(12)61728-0
   Web of Science ®Google Scholar
• SullivanSDRamseySDLeeTAThe economic burden of COPDChest2000117Suppl 2S5S910.1378/chest.117.2_suppl.5S
   PubMed Web of Science ®Google Scholar
• LopezADShibuyaKRaoCChronic obstructive pulmonary disease: current burden and future projectionsEur Respir J200627239741210.1183/09031936.06.0002580516452599
   PubMed Web of Science ®Google Scholar
• MathersCDLoncarDProjections of global mortality and burden of disease from 2002 to 2030PLoS Med2006311e44210.1371/journal.pmed.003044217132052
   PubMed Web of Science ®Google Scholar
• VosTFlaxmanADNaghaviMYears lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201238098592163219610.1016/S0140-6736(12)61729-223245607
   PubMed Web of Science ®Google Scholar
• Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)2018 Available from: http://www.goldcopd.orgAccessed November 15, 2017
   Google Scholar
• AnzuetoAFergusonGTFeldmanGEffect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomesCOPD20096532032919863361
   PubMedGoogle Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578910.1056/NEJMoa06307017314337
   PubMed Web of Science ®Google Scholar
• FergusonGTAnzuetoAFeiREmmettAKnobilKKalbergCEffect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbationsRespir Med200810281099110810.1016/j.rmed.2008.04.01918614347
   PubMed Web of Science ®Google Scholar
• JenkinsCRJonesPWCalverleyPMEfficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH studyRespir Res20091015910.1186/1465-9921-10-3119566934
   PubMed Web of Science ®Google Scholar
• YangIAClarkeMSSimEHFongKMInhaled corticosteroids for stable chronic obstructive pulmonary diseaseCochrane Database of Syst Rev20127CD002991
   PubMed Web of Science ®Google Scholar
• CrimCDransfieldMTBourbeauJPneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPDAnn Am Thorac Soc2015121273410.1513/AnnalsATS.201409-413OC25490706
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110310.1056/NEJMoa100837821428765
   PubMed Web of Science ®Google Scholar
• VestboJAndersonJABrookRDFluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trialLancet2016387100301817182610.1016/S0140-6736(16)30069-127203508
   PubMed Web of Science ®Google Scholar
• MapelDSchumMYoodMBrownJMillerDDavisKPneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilatorsPrim Care Respir J201019210911710.4104/pcrj.2009.0007220082059
   PubMedGoogle Scholar
• SharafkhanehASouthardJGGoldmanMUryniakTMartinUJEffect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized studyRespir Med2012106225726810.1016/j.rmed.2011.07.02022033040
   PubMed Web of Science ®Google Scholar
• RennardSITashkinDPMcElhattanJEfficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trialDrugs200969554956510.2165/00003495-200969050-0000419368417
   PubMed Web of Science ®Google Scholar
• CalverleyPMBoonsawatWCsekeZZhongNPetersonSOlssonHMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J200322691291914680078
   PubMed Web of Science ®Google Scholar
• SzafranskiWCukierARamirezAEfficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J2003211748112570112
   PubMed Web of Science ®Google Scholar
• TashkinDPRennardSIMartinPEfficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trialDrugs200868141975200010.2165/00003495-200868140-0000418778120
   PubMed Web of Science ®Google Scholar
• FergusonGTTashkinDPSkärbyTEffect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: the 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) studyRespir Med2017132314110.1016/j.rmed.2017.09.00229229103
   PubMed Web of Science ®Google Scholar
• HigginsJPTGreenSCochrane Handbook for Systematic Reviews of Interventions Version 510 The Cochrane CollaborationNew YorkWiley2014 [updated 2011]. Available from: http://handbook.cochrane.orgAccessed August 16, 2014
   Google Scholar
• BeggCBMazumdarMOperating characteristics of a rank correlation test for publication biasBiometrics1994504108811017786990
   PubMed Web of Science ®Google Scholar
• ZhongNZhengJWenFEfficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary diseaseCurr Med Res Opin201228225726510.1185/03007995.2011.63642022046961
   PubMed Web of Science ®Google Scholar
• FukuchiYSamoroRFassakhovRBudesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study resultsRespirology201318586687310.1111/resp.1209023551359
   PubMed Web of Science ®Google Scholar
• NanniniLJPoolePMilanSJKestertonACombined corticosteroid and long-acting beta2-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20138CD006826
   PubMed Web of Science ®Google Scholar
• NanniniLJLassersonTJPoolePCombined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20129CD006829
   PubMed Web of Science ®Google Scholar
• NanniniLJPoolePMilanSJHolmesRNormansellRCombined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev201311CD003794
   PubMed Web of Science ®Google Scholar
• HalpinDGrayJEdwardsSMoraisJSinghDBudesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trialsInt J Clin Pract201165776477410.1111/j.1742-1241.2011.02685.x21676119
   PubMed Web of Science ®Google Scholar
• EdsbäckerSWollmerPSelroosOBorgströmLOlssonBIngelfJDo airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids?Pulm Pharmacol Ther200821224725810.1016/j.pupt.2007.08.00517950641
   PubMed Web of Science ®Google Scholar
• van den BrinkKIBoorsmaMStaalvan den BrekelAJEdsbäckerSWoutersEFThorssonLEvidence of the in vivo esterification of budesonide in human airwaysBr J Clin Pharmacol2008661273510.1111/j.1365-2125.2008.03164.x18384442
   PubMed Web of Science ®Google Scholar
• SethiSMaloneyJGroveLWronaCBerensonCSAirway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2006173999199810.1164/rccm.200509-1525OC16474030
   PubMed Web of Science ®Google Scholar
• EkALarssonKSiljerudSPalmbergLFluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophagesAllergy199954769169910442524
   PubMed Web of Science ®Google Scholar
• LöfdahlCGEricssonASvenssonKAndreassonECost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alonePharmacoeconomics200523436537510.2165/00019053-200523040-0000615853436
   PubMed Web of Science ®Google Scholar